| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, …
Over the last 12 months, insiders at PMV Pharmaceuticals, Inc. have bought $0 and sold $0 worth of PMV Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at PMV Pharmaceuticals, Inc. have bought $0 and sold $2.4M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,900,000 shares for transaction amount of $34.2M was made by RA CAPITAL MANAGEMENT, L.P. (10 percent owner) on 2020‑09‑29.
| 2025-09-10 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 500,000 1.3373% | $1.80 | $900,000 | +1.57% | |
| 2025-07-01 | Sale | Mack David Henry | President and CEO | 58,411 0.114% | $1.06 | $62,179 | +26.67% | |
| 2025-07-01 | Sale | Ticktin Robert | General Counsel & COO | 23,151 0.0452% | $1.06 | $24,651 | +26.67% | |
| 2025-07-01 | Sale | Jalota Deepika | Chief Development Officer | 33,065 0.0645% | $1.06 | $35,198 | +26.67% | |
| 2025-07-01 | Sale | Carulli Michael | Chief Financial Officer | 28,249 0.0551% | $1.06 | $30,077 | +26.67% | |
| 2024-09-11 | Sale | Jalota Deepika | Chief Development Officer | 7,218 0.0141% | $1.50 | $10,853 | -5.96% | |
| 2024-09-11 | Sale | Carulli Michael | Chief Financial Officer | 2,891 0.0057% | $1.50 | $4,347 | -5.96% | |
| 2023-11-22 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 87,786 0.1816% | $2.23 | $195,763 | -25.56% | |
| 2023-09-15 | Sale | Alland Leila | Chief Medical Officer | 6,291 0.0128% | $6.62 | $41,646 | -74.14% | |
| 2023-09-15 | Sale | Jalota Deepika | Chief Development Officer | 4,104 0.0084% | $6.62 | $27,168 | -74.14% | |
| 2022-05-26 | Sale | OrbiMed Genesis GP LLC | 26,253 0.0695% | $15.93 | $418,210 | -25.36% | ||
| 2022-03-29 | Sale | ORBIMED CAPITAL LLC | 365,000 0.7867% | $21.52 | $7.85M | -45.86% | ||
| 2021-10-06 | Sale | Schroeder Thilo | director | 800 0.0019% | $30.15 | $24,120 | -43.26% | |
| 2021-10-04 | Sale | Schroeder Thilo | director | 100 0.0002% | $30.08 | $3,008 | -43.75% | |
| 2021-10-01 | Sale | Schroeder Thilo | director | 11,541 0.0255% | $30.10 | $347,384 | -46.13% | |
| 2021-09-30 | Sale | Schroeder Thilo | director | 2,978 0.0066% | $30.03 | $89,429 | -45.30% | |
| 2021-09-29 | Sale | Schroeder Thilo | director | 5,708 0.0127% | $30.04 | $171,468 | -45.33% | |
| 2021-09-27 | Sale | Schroeder Thilo | director | 1,753 0.004% | $30.11 | $52,783 | -44.51% | |
| 2021-09-22 | Sale | Schroeder Thilo | director | 100 0.0002% | $30.00 | $3,000 | -41.71% | |
| 2021-09-22 | Sale | LEVINE ARNOLD J | director | 3,500 0.0082% | $30.00 | $105,000 | -41.71% |
| ORBIMED ADVISORS LLC | 10 percent owner | 5975291 11.204% | $8.25M | 1 | 2 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 1710265 3.2068% | $2.36M | 1 | 0 | <0.0001% |
| Boxer Capital, LLC | 950000 1.7813% | $1.31M | 1 | 0 | <0.0001% | |
| Thompson Peter A. | 475000 0.8907% | $655,500.00 | 1 | 0 | <0.0001% | |
| ORONSKY ARNOLD L | 55555 0.1042% | $76,665.90 | 1 | 0 | <0.0001% | |
| INTERWEST PARTNERS X LP | director | 55555 0.1042% | $76,665.90 | 1 | 0 | <0.0001% |
$5,831,763 | 118 | -33.78% | $66.68M | |
$9,405,928 | 107 | 12.61% | $74.85M | |
$17,525,882 | 60 | 5.22% | $64.7M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$909,129 | 37 | 42.19% | $67.23M |
| Increased Positions | 33 | +47.83% | 2M | +6.53% |
| Decreased Positions | 28 | -40.58% | 2M | -6.49% |
| New Positions | 11 | New | 238,129 | New |
| Sold Out Positions | 10 | Sold Out | 375,502 | Sold Out |
| Total Postitions | 74 | +7.25% | 37M | +0.05% |
| Orbimed Advisors Llc | $7,350.00 | 11.27% | 5.98M | -500,000 | -7.72% | 2025-09-30 |
| Bml Capital Management, Llc | $6,509.00 | 9.99% | 5.29M | +292,000 | +5.84% | 2025-09-30 |
| Tang Capital Management Llc | $5,886.00 | 9.03% | 4.79M | +5M | New | 2025-09-30 |
| Arrowmark Colorado Holdings Llc | $4,061.00 | 6.23% | 3.3M | +113,225 | +3.55% | 2025-09-30 |
| Sio Capital Management, Llc | $3,243.00 | 4.97% | 2.64M | -1M | -29.42% | 2025-09-30 |
| Euclidean Capital Llc | $3,232.00 | 4.96% | 2.63M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,661.00 | 4.08% | 2.16M | +9,427 | +0.44% | 2025-09-30 |
| Acadian Asset Management Llc | $2,541.00 | 3.9% | 2.07M | 0 | 0% | 2025-09-30 |
| Stonepine Capital Management, Llc | $1,685.00 | 2.59% | 1.37M | +524,171 | +61.96% | 2025-09-30 |
| Blackrock, Inc. | $1,358.00 | 2.08% | 1.1M | -36,452 | -3.2% | 2025-09-30 |